Bioenvision shareholders to vote Friday on Genzyme takeover

ValBrickates Kennedy

BOSTON (MarketWatch) -- Bioenvision Inc.
bivn
said late Thursday that it will hold a final vote on whether to accept a takover bid by Genzyme Corp.
genz
at a special shareholders meeting on Friday. The meeting will begin at 11 a.m. ET. Genzyme has proposed buying Bioenvision for $5.60 a share, or about $345 million.

Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.